160 related articles for article (PubMed ID: 2961937)
1. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
[TBL] [Abstract][Full Text] [Related]
4. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
5. Benefits of combination therapy with flutamide in patients relapsing after castration.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Monfette G; Emond J; Bergeron N
Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
[TBL] [Abstract][Full Text] [Related]
6. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
7. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
Labrie F; Dupont A; Cusan L; Manhès G; Bergeron N; Lacourcière Y; Pineault S; Bélanger A; Monfette G; Emond J
J Steroid Biochem; 1989 Oct; 33(4B):817-21. PubMed ID: 2689788
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.
Labrie F; Dupont A; Bélanger A; Cusan L; Giguère M; Lacourcière Y; Luthy I; Bégin D; Labrie C; Simard J
Cancer Metastasis Rev; 1987; 6(4):615-36. PubMed ID: 3327635
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.
Labrie F; Dupont A; Belanger A; Giguere M; Lacoursiere Y; Emond J; Monfette G; Bergeron V
J Steroid Biochem; 1985 Nov; 23(5B):833-41. PubMed ID: 2934579
[TBL] [Abstract][Full Text] [Related]
11. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
[TBL] [Abstract][Full Text] [Related]
12. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Lacoste D; Dubé D; Bélanger A; Labrie F
Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.
Labrie F; Dupont A; Cusan L; Gomez J; Emond J; Monfette G
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):943-50. PubMed ID: 2285608
[TBL] [Abstract][Full Text] [Related]
15. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
St-Arnaud R; Lachance R; Kelly SJ; Belanger A; Dupont A; Labrie F
Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
[TBL] [Abstract][Full Text] [Related]
16. Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
Kung TT; Mingo GG; Siegel MI; Watnick AS
Prostate; 1988; 12(4):357-63. PubMed ID: 3134647
[TBL] [Abstract][Full Text] [Related]
17. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
Dupont A; Cusan L; Gomez JL; Koutsilieris M; Suburu R; Emond J; Labrie F
Br J Urol; 1993 Nov; 72(5 Pt 1):629-34. PubMed ID: 10071551
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of flutamide action on prostatic and testicular functions in the rat.
Marchetti B; Labrie F
J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
[TBL] [Abstract][Full Text] [Related]
20. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Labrie F; Dupont A; Cusan L; Gomez JL; Diamond P
Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
